MedTrace Logo

A Case Control Study of Resveratrol Effects in Coronary Artery Disease Patients With Metabolic Syndrome

NCT02137421 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2017-05-02

No results posted yet for this study

Summary

The aim of this study is to explore the role of Canonical β-catenin/Wnt and forkhead box O (FOXO) pathways by means of investigating their target genes in coronary artery disease (CAD) pathogenesis and to examine the effects of resveratrol (RES) on these pathways in CAD patients.

Conditions

Interventions

DIETARY_SUPPLEMENT

Resveratrol (3, 4´, 5 trihydroxystilbene)

Resveratrol (RES) (3, 4´, 5 trihydroxystilbene)

Sponsors & Collaborators

  • Tehran University of Medical Sciences

    lead OTHER

Principal Investigators

  • Taghi Golmohammadi, PhD · Tehran University of Medical Sciences

  • Arash Hosseinnejad, MD-PhD · Tehran University of Medical Sciences

  • Reza Meshkani, PhD · Tehran University of Medical Sciences

  • Mahmoud Shirzad, MD · Tehran Heart Center,Tehran University of Medical Sciences

  • Mehrnoosh Shanaki Bavarsad, PhD student · Tehran University of Medical Sciences

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
40 Years
Max Age
55 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-04-30
Primary Completion
2014-08-31
Completion
2014-12-31

Countries

  • Iran

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02137421 on ClinicalTrials.gov